Literature DB >> 28277923

3D Culture as a Clinically Relevant Model for Personalized Medicine.

Eliza Li Shan Fong1, Tan Boon Toh2, Hanry Yu1,3,4, Edward Kai-Hua Chow2,5.   

Abstract

Advances in understanding many of the fundamental mechanisms of cancer progression have led to the development of molecular targeted therapies. While molecular targeted therapeutics continue to improve the outcome for cancer patients, tumor heterogeneity among patients, as well as intratumoral heterogeneity, limits the efficacy of these drugs to specific patient subtypes, as well as contributes to relapse. Thus, there is a need for a more personalized approach toward drug development and diagnosis that takes into account the diversity of cancer patients, as well as the complex milieu of tumor cells within a single patient. Three-dimensional (3D) culture systems paired with patient-derived xenografts or patient-derived organoids may provide a more clinically relevant system to address issues presented by personalized or precision medical approaches. In this review, we cover the current methods available for applying 3D culture systems toward personalized cancer research and drug development, as well as key challenges that must be addressed in order to fully realize the potential of 3D patient-derived culture systems for cancer drug development. Greater implementation of 3D patient-derived culture systems in the cancer research field should accelerate the development of truly personalized medical therapies for cancer patients.

Entities:  

Keywords:  3D; high-content screening; personalized medicine; spheroids; tumor models

Mesh:

Substances:

Year:  2017        PMID: 28277923     DOI: 10.1177/2472630317697251

Source DB:  PubMed          Journal:  SLAS Technol        ISSN: 2472-6303            Impact factor:   3.047


  14 in total

Review 1.  Human Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment Selection.

Authors:  Katherine A Johnson; Rebecca A DeStefanis; Philip B Emmerich; Patrick T Grogan; Jeremy D Kratz; Sarbjeet K Makkar; Linda Clipson; Dustin A Deming
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

Review 2.  Theranostic Nanoparticles for Tracking and Monitoring Disease State.

Authors:  Cristina Zavaleta; Dean Ho; Eun Ji Chung
Journal:  SLAS Technol       Date:  2017-11-08       Impact factor: 3.047

Review 3.  In Vitro 3D Cultures to Reproduce the Bone Marrow Niche.

Authors:  Justin Ham; Lauren Lever; Maura Fox; Michaela R Reagan
Journal:  JBMR Plus       Date:  2019-10-01

Review 4.  Challenges of applying multicellular tumor spheroids in preclinical phase.

Authors:  Se Jik Han; Sangwoo Kwon; Kyung Sook Kim
Journal:  Cancer Cell Int       Date:  2021-03-04       Impact factor: 5.722

Review 5.  Cell Sources for Human In vitro Bone Models.

Authors:  Sana Ansari; Keita Ito; Sandra Hofmann
Journal:  Curr Osteoporos Rep       Date:  2021-01-15       Impact factor: 5.096

Review 6.  Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.

Authors:  Engin Ulukaya; Didem Karakas; Konstantinos Dimas
Journal:  Medicina (Kaunas)       Date:  2021-06-19       Impact factor: 2.430

7.  Looking to the future of organs-on-chip.

Authors:  John Greenman
Journal:  Future Sci OA       Date:  2017-05-26

Review 8.  3D tissue engineering, an emerging technique for pharmaceutical research.

Authors:  Gregory Jensen; Christian Morrill; Yu Huang
Journal:  Acta Pharm Sin B       Date:  2018-03-21       Impact factor: 11.413

Review 9.  Critical considerations for targeting colorectal liver metastases with nanotechnology.

Authors:  Usman Arshad; Paul A Sutton; Marianne B Ashford; Kevin E Treacher; Neill J Liptrott; Steve P Rannard; Christopher E Goldring; Andrew Owen
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-09-30

10.  Combined transmission, dark field and fluorescence microscopy for intact, 3D tissue analysis of biopsies.

Authors:  Marius I Boamfa; Michel J A Asselman; Roland C M Vulders; Esther I Verhoef; Martin E van Royen; Pieter J van der Zaag
Journal:  J Biomed Opt       Date:  2020-11       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.